ARase Therapeutics

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

Accent Therapeutics

This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.

AdoRx Therapeutics

This company develops small-molecule adenosine receptor antagonists for pharmaceutical partners to treat cancer by disrupting immune evasion in the tumour microenvironment.

Scorpion Therapeutics

This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Ribon Therapeutics

This biotechnology company develops small molecule inhibitors targeting stress support pathways for patients with cancer and inflammatory diseases.

Arrakis Therapeutics

This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.

Azeria Therapeutics

The company develops small molecule drugs targeting pioneer factors to treat hormone-resistant breast and prostate cancer patients.